Protein Crystallography at Hinxton Hall, Cambridge
News Apr 16, 2008
ELRIG has a well earned reputation for producing, informative, educational Conferences and the recent Protein Crystallography Conference was no exception.
Although this was a very focused meeting we attracted 31 exhibitor stands and an audience of dedicated Crystallographers, who were treated to 2 Keynote Presentations from eminent speakers, Prof. Sir Tom Blundell and Prof So Iwata, both representing academia.
A huge thanks go to all the Speakers for addressing the issues, presenting real data and for highlighting the technologies and approaches in such an open and informative way. The feedback from the attendees has been very positive and I think the crystallography community both enjoyed and learnt from the experience.
News from the Vendors was also very favourable with lots of new delegates to talk to they were busy during all the breaks.
The ‘Satellite Navigation System’ was won by Chuka Umeano of Oxford Uni., for completing his Feedback Survey Form. With Rigaku winning the Vendor ‘Technology’ prize for the Most Innovative New Technology.
The next two meetings during 2008 are:
ADME the Application of Laboratory Automation being held at Johnson & Johnson, Belgium on 12th June, our first European meeting.
Plus the largest Drug Discovery meeting in Europe being held at the BIC, Bournemouth on 23rd and 24th September.
Please ensure both dates are in your diaries, don’t be disappointed, inform your Marketing Departments to have ELRIG booked into their budgets.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE